Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, Pfizer RSV vaccine sales fall in US
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
GSK RSV vaccine data suggest protection across 3 seasons
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
A GSK spokesperson said 9 million Americans, or two-thirds of the market, have been vaccinated against RSV with Arexvy and that the company sees opportunities for strong growth in
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.
McKnight's Long-Term Care News
1d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
14h
What you need to know about the new RSV vaccine
As the days grow cooler, families across Utah are reminded that respiratory viruses, particularly Respiratory Syncytial Virus ...
2d
RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
pulmonologyadvisor
10h
RSV Vaccine in Older Adults Reduces Risk for Infection, Hospitalization
RSV vaccination was associated with decreased risks for infection and hospitalization, although the decrease was not statistically significant.
1d
Alberta to cover pricey RSV vaccine for some older people
The Alberta government announced Monday that the RSV vaccine, Abyrsvo, will be provincially funded for Albertans, aged 60 and ...
2d
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
8h
on MSN
Respiratory virus season is back. Here's how to protect against flu, COVID-19 and RSV
Flu, COVID-19 and RSV are predicted to cause about as many hospitalizations as last year. Houston experts offer tips for ...
thecardiologyadvisor.com
14h
RSV Vaccine Is Recommended for Long-Term Care Facility Residents
The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.
7d
Everything You Need to Know About Getting the RSV Vaccine During Pregnancy
If you, for some reason, don’t get the RSV vaccine while you’re pregnant, you can (and should!) still protect your baby after ...
cidrap.umn
2d
Mpox vaccine campaign launches in DRC, with first doses to healthcare workers
Over the weekend, the World Health Organization (WHO) confirmed it began a Jynneos vaccination campaign in the Democratic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
COVID
Pfizer
GSK
GlaxoSmithKline
United States
Feedback